Tower Research Capital (TRC)’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,221
| Closed | -$49.1K | – | 5200 |
|
|
2026
Q1 | $49.1K | Buy |
1,221
+902
| +283% | +$19.4K | ﹤0.01% | 2751 |
|
|
2025
Q4 | $8.01K | Sell |
319
-7,076
| -96% | -$166K | ﹤0.01% | 3970 |
|
|
2025
Q3 | $167K | Buy |
7,395
+5,828
| +372% | +$136K | ﹤0.01% | 1610 |
|
|
2025
Q2 | $27.1K | Sell |
1,567
-4,933
| -76% | -$91.3K | ﹤0.01% | 3480 |
|
|
2025
Q1 | $142K | Sell |
6,500
-13,465
| -67% | -$372K | ﹤0.01% | 1570 |
|
|
2024
Q4 | $637K | Buy |
19,965
+14,654
| +276% | +$441K | 0.01% | 902 |
|
|
2024
Q3 | $153K | Sell |
5,311
-2,009
| -27% | -$74.4K | ﹤0.01% | 1872 |
|
|
2024
Q2 | $281K | Buy |
7,320
+6,894
| +1,618% | +$312K | ﹤0.01% | 1821 |
|
|
2024
Q1 | $25K | Sell |
426
-3,682
| -90% | -$235K | ﹤0.01% | 2798 |
|
|
2023
Q4 | $246K | Buy |
4,108
+3,132
| +321% | +$159K | ﹤0.01% | 1931 |
|
|
2023
Q3 | $37.1K | Sell |
976
-6,233
| -86% | -$274K | ﹤0.01% | 2831 |
|
|
2023
Q2 | $657K | Buy |
7,209
+4,638
| +180% | +$400K | 0.02% | 796 |
|
|
2023
Q1 | $170K | Buy |
2,571
+1,712
| +199% | +$98.8K | 0.01% | 1458 |
|
|
2022
Q4 | $44K | Sell |
859
-7,686
| -90% | -$408K | ﹤0.01% | 2444 |
|
|
2022
Q3 | $584K | Sell |
8,545
-6,554
| -43% | -$388K | 0.01% | 1019 |
|
|
2022
Q2 | $683K | Buy |
15,099
+4,033
| +36% | +$184K | 0.02% | 934 |
|
|
2022
Q1 | $562K | Sell |
11,066
-350
| -3% | -$15.5K | 0.01% | 1083 |
|
|
2021
Q4 | $539K | Sell |
11,416
-4,728
| -29% | -$186K | 0.01% | 1067 |
|
|
2021
Q3 | $532K | Buy |
16,144
+11,033
| +216% | +$620K | 0.01% | 936 |
|
|
2021
Q2 | $323K | Buy |
5,111
+1,662
| +48% | +$85.8K | 0.01% | 1536 |
|
|
2021
Q1 | $148K | Buy |
3,449
+1,704
| +98% | +$80.6K | ﹤0.01% | 2260 |
|
|
2020
Q4 | $100K | Sell |
1,745
-1,260
| -42% | -$53.3K | ﹤0.01% | 2340 |
|
|
2020
Q3 | $91K | Sell |
3,005
-5,647
| -65% | -$169K | ﹤0.01% | 3211 |
|
|
2020
Q2 | $283K | Buy |
+8,652
| New | +$278K | 0.01% | 1493 |
|
|
2020
Q1 | – | Sell |
-270
| Closed | -$8K | – | 3005 |
|
|
2019
Q4 | $8K | Sell |
270
-4,905
| -95% | -$136K | ﹤0.01% | 2427 |
|
|
2019
Q3 | $124K | Buy |
5,175
+3,648
| +239% | +$100K | 0.01% | 1223 |
|
|
2019
Q2 | $39K | Buy |
+1,527
| New | +$31.1K | ﹤0.01% | 1752 |
|
|
2018
Q4 | – | Sell |
-2,704
| Closed | -$48K | – | 3796 |
|
|
2018
Q3 | $48K | Buy |
+2,704
| New | +$50K | ﹤0.01% | 1781 |
|
|
2018
Q2 | – | Sell |
-405
| Closed | -$9K | – | 3611 |
|
|
2018
Q1 | $9K | Buy |
+405
| New | +$7.96K | ﹤0.01% | 2488 |
|
Other funds holding APLS
Tower Research Capital (TRC)'s APLS Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,221 shares — an estimated $49.1K sold.
Tower Research Capital (TRC) first reported a position in APLS in Q1 2018 and held it in 29 quarters. The position peaked at $683K in Q2 2022. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,221 Apellis Pharmaceuticals shares in Q2 2026, an estimated $49.1K.
- Tower Research Capital (TRC) first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 29 quarters.
- Tower Research Capital (TRC)'s Apellis Pharmaceuticals position peaked at $683K in Q2 2022.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.